<DOC>
	<DOCNO>NCT01704404</DOCNO>
	<brief_summary>This study characterize dose response TD-4208 7 day dose subject Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>7 Days TD−4208 Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Subject male female age 40 75 year ( inclusive , randomization ) . 2 . Subject : Has FEV1/FVC ( forced expiratory volume 1 second/forced vital capacity ) &lt; 0.7 screening ; Has postbronchodilator FEV1 screen 30 % 80 % ( inclusive ) predict normal value . 3 . Subject demonstrate screen least 120 mL increase FEV1 within 1 hour receive 500 µg ipratropium bromide PARI LC Sprint® nebulizer . 4 . Females nonchildbearing potential . All male subject must agree use highly effective method birth control partner childbearing potential study 1 month completion study dose . 5 . Subject ( care giver ) able properly prepare administer study medication . 6 . Subject willing able give write informed consent participate . 1 . Subject COPD exacerbation lung infection within 6 week randomization . 2 . Subject initiation treatment , change dose , inhaled oral corticosteroid , longacting beta2 agonist ( LABA ) , longacting muscarinic antagonist ( LAMA ) within 4 week qualify ipratropium bromide response test . 3 . Subject take daily maintenance inhaled/systemic corticosteroid ( &gt; 1000 μg fluticasone propionate equivalent ≥10 mg prednisone ) . 4 . Subject uncontrolled hematologic , immunologic , renal , neurologic , hepatic , endocrine , disease condition base information gather medical history , physical examination , laboratory finding might place subject undue risk potentially compromise result interpretation study . 5 . Subject history significant cerebrovascular disease , coronary artery disease , cardiac arrhythmia . Subject history ( family history ) congenital prolong QTc ( correct QT interval ) syndrome abnormal clinically significant electrocardiogram ( ECG ) screening , include QTcB ( QT interval correct heart rate use Bazett 's formula ) value &gt; 450 msec ( male ) &gt; 470 msec ( female ) ; show evidence clinically significant rhythm abnormality . 6 . Subject know hypersensitivity TD4208 similar drug class . 7 . Subject history alcoholism drug abuse within 2 year prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Long act muscarinic antagonist</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>